B · Normal
[Changchun High-tech: Subsidiary GenSci133 injection clinical trial application approved] On September 4th, Changchun High-tech (000661.SZ) announced that the company's controlled subsidiary Jinsai Pharmaceutical received the "Drug Clinical Trial Approval Notice" approved and issued by the State Food and Drug Administration, and the domestically produced drug registration clinical trial application for GenSci133 injection was approved and is intended to be used to treat osteoporosis. The drug is a self-developed fusion protein of PTH analog and RANKL antibody. It belongs to Category 1 therapeutic biological products and is expected to be administered by subcutaneous injection every 3 to 6 months.
Comments